Member Info for quercusrobor

1..Could some kind person pls explain in simple language EXACTLY what it is that Syme do....have listened to several interviews with AZ on Proactive etc and am still no further forward.
2.Who apart from AZ is in an executive position on the BOD?
3.I was unable to find the signicant shareholders on the website...hlp needed pls.
tx in advance....

re...Hmm he disappeared in NCYT when he sold out...
RichKen
Posted in: AVCT

Posts: 3,551

Price: 163.00

Strong Buy
RE: BAMS and The Spectometer Fired by Affimer

27 Aug 2020 12:47

I would not be surprised to see Avacta using specific Affimers in BAMS offering screening to show, if the symptoms are Covid19/flu/a common cold, similar to the announcement from Novacyt. How easy would it be for Affimer Technology to be used in this way. We have already said we can use BAMS to identify mutations if the virus, so to identify common Covid strains should be easy.
Cheers Rich

ridiculous comment.....

either you are being mischievous...putting it mildy....or you're so lacking in confidence that you need constant reassurance...

....do you wet the bed too?

re... It would be helpful if you could answer the questions put to you from your first post.

took the words out of my mouth;)....
await answers with interest....particularly...

which other antigen, 10 minute, pregnancy style, DIY and cheap do you have that has been first in the market? Please, can you answer that....
tx

https://www.ii.co.uk/analysis-commentary/eurasia-mining-further-growth-potential-cards-ii513295

Eurasia Mining: further growth potential on the cards?
by Alistair Strang from Trends and Targets | 26th August 2020 10:49

...on the fast spin cycle.

re..I suspect much of the selling
# Trades 402
Vol. Sold 163,603
Sold Value £276.49k
Vol. Bought 654,569
Bought Value £1m
am I missing something?

https://twitter.com/JordanBMZ/status/1296767875714371584?s=20

hTTps://twitter.com/JordanBMZ/status/1296767875714371584?s=20

hTTps://twitter.com/JordanBMZ/status/1296767875714371584?s=20

hardan Bank analyst, only the other day, initiating 450p target going off this.
??
#DDDD
hTTps://twitter.com/JordanBMZ/status/1296767875714371584?s=20

??
#DDDD

Rapid pregnancy-style home Covid tests that can produce results in the time it takes to eat your cornflakes could be approved within weeks, top UK scientific adviser claims
https://www.dailymail.co.uk/news/article-8647635/Rapid-pregnancy-style-tests-Covid-19-eat-cornflakes-sold-5.html

The Stigologist
20 Aug '20 - 08:47 - 7336 of 7344
0 2 0
New 4D Pharma Telegram Research group

**********************PpKJWB2zBb_4gskYZn_SUA

edit....o/bought!

looks like a perfect gap filling exercise from here..............def no sell signal,a gentle unwinding from o/sold .....as expected.

re...realistically we have risen a lot without 4D issuing any RNS just purely on the back of Seres,
maybe to some extent......but a mcap of 117m.....is still way off fair value....SNG @ >300m...really?

https://twitter.com/duttonjonathan/status/1292910112424722434

Ideas wanted for 10 AIM 10x multibaggers for the next 10 years. Focus on disruptive technologies, preferably with a MOAT. My short list of 10 is: #AVCT #DDDD #EQT #IKA #MXCT #PYC #RENX #SCE #TILS #VDTK More suggestions welcomed!

https://twitter.com/MylesMcNulty/status/1293078816793997312

Seres Therapeutics, Inc. (MCRB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
31.08+26.44 (+569.83%)

Live Palladium Price
MARKET IS OPEN (Will close in 7 hrs. 15 mins.)
Aug 10, 2020 09:46 NY Time
US Dollar
2,151.00Bid
2,321.00Ask
High: 2,325.00Low: 2,028.00
+120.00 +5.91

The Stigologist
10 Aug '20 - 12:17 - 6545 of 6545
0 4 0
Mikhaila Peterson daughter of Jordan Peterson claiming #FMT cured her c.difficile

All this is HUGE for 4D

hTtps://twitter.com/Stockonomist/status/1292776155439935488?s=20

https://www.businesswire.com/news/home/20200810005194/en/Seres-Therapeutics-Announces-Positive-Topline-Results-SER-109

Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
– SER-109 met Phase 3 primary endpoint, showing a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared to placebo –
– SER-109 was well tolerated, with a safety profile comparable to placebo –
– Efficacy results substantially exceeded FDA regulatory guidance to support BLA filing as a single pivotal trial; Company to meet with agency to discuss filing for product approval as soon as possible –
– Positive SER-109 Phase 3 data provide validation for Seres’ microbiome therapeutics platform and further development of its pipeline of product candidates –